Research map: Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial

Back to the article

Papers in this map

  1. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer · Martin Reck · 2016 · 10309 citations · Cited by this paper
  2. Pancreatic ductal adenocarcinoma: integrating molecular insights for targeted interventions · Ganji Purnachandra Nagaraju · 2026 · 4 citations · Cites this paper
  3. HBO1 suppresses anti-tumor immunity of CD8⁺ T Cells in thyroid cancer by recruiting BRD4 to regulate VTCN1 expression · 2026 · Related
  4. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer · Leena Gandhi · 2018 · 6765 citations · Cited by this paper
  5. The prognostic impact of surufatinib for the treatment of advanced pancreatic ductal adenocarcinoma: a single center real-world retrospective study · Yanzhen Yang · 2025 · 1 citation · Cites this paper
  6. Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma · 2026 · Related
  7. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC · Mark A. Socinski · 2018 · 3818 citations · Cited by this paper
  8. Overcoming Immunotherapy Resistance in Small-Cell Lung Cancer · Matteo Canale · 2026 · 1 citation · Cites this paper
  9. Impact of neck nodal yield on immune checkpoint inhibitor outcome after recurrence in head and neck squamous cell carcinoma · 2026 · Related
  10. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer · Luis G Paz-Ares · 2018 · 3711 citations · Cited by this paper
  11. Efficacy and safety of surufatinib plus PD-1/PD-L1 inhibitors as first-line maintenance therapy in extensive-stage small cell lung cancer · Haitao Tao · 2026 · Cites this paper
  12. Preclinical efficacy of iPSC-derived MUC1-targeted CAR-NK cells against esophageal squamous cell carcinoma · 2026 · Related
  13. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial · Tony S.K. Mok · 2019 · 3390 citations · Cited by this paper
  14. Targeting vascular endothelial growth factor and its receptors in non-small cell lung cancer for improved treatment strategies · Rajesh B. Nanaware · 2026 · Cites this paper
  15. Survival outcomes of conversion curative therapy following atezolizumab–bevacizumab in advanced hepatocellular carcinoma · 2026 · Related
  16. Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment · Narjust Duma · 2019 · 2289 citations · Cited by this paper
  17. Integrative single-cell and multi-omics analysis of ZBTB21-mediated serine metabolism in colorectal cancer: from metabolic reprogramming to immune microenvironment modulation · 2026 · Related
  18. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial · Luis G Paz-Ares · 2021 · 1397 citations · Cited by this paper
  19. Squeezing Treatment-Induced Metabolic Alterations in Melanoma Cells Are Accompanied by Impaired Cluster of Differentiation 8-Positive T Cell and Natural Killer Cell Antitumor Effector Functions · 2026 · Related
  20. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ · Anne‐Marie C. Dingemans · 2021 · 626 citations · Cited by this paper
  21. Efficacy and safety of anti-PD-1 combined with IFN-α1b with or without anlotinib as the first-line therapy in patients with unresectable advanced melanoma: a real-world cohort study · 2026 · Related
  22. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial · José Manuel Trigo · 2020 · 488 citations · Cited by this paper
  23. Spatially fractionated radiotherapy with PD-L1 blockade achieves superior antitumor efficacy and safety in a preclinical model of peritoneal metastasis · 2026 · Related
  24. Untitled · Cited by this paper
  25. Untitled · Cited by this paper
  26. Untitled · Cited by this paper
  27. Untitled · Cited by this paper
  28. Untitled · Cited by this paper
  29. Untitled · Cited by this paper
  30. Untitled · Cited by this paper
  31. Untitled · Cited by this paper
  32. Untitled · Cited by this paper
  33. Untitled · Cited by this paper
  34. Untitled · Cited by this paper
  35. Untitled · Cited by this paper
  36. Untitled · Cited by this paper
  37. Untitled · Cited by this paper
  38. Untitled · Cited by this paper
  39. Untitled · Cited by this paper

Source: OpenAlex (CC0)